Treatment of apathy with methylphenidate
Prasad R Padala1, William J Burke, Subhash C Bhatia
1Veterans Affairs Medical Center, 4101 Woolworth Avenue, Omaha, NE 68105, USA. ppadala@unmc.edu
Apathy, a common condition across psychiatric diagnoses, lacks studied treatments. Methylphenidate showed significant improvement in apathy, motivation, novelty, and persistence in four case studies.
Area of Science:
- Neuroscience
- Psychiatry
Background:
- Apathy is a prevalent condition frequently observed across diverse psychiatric diagnoses.
- Effective treatment strategies for apathy remain underexplored in clinical research.
Observation:
- The study presents four distinct cases of patients experiencing apathy.
- These patients were treated using a consistent regimen of methylphenidate.
Findings:
- A notable improvement in apathy symptoms was observed following methylphenidate treatment.
- Specific sub-domains of apathy, including motivation, novelty-seeking, and persistence, showed significant positive changes.
Implications:
- Methylphenidate may represent a potential therapeutic option for managing apathy.
- Further research is warranted to validate these findings in larger, controlled studies.
More Related Videos
04:24Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
Published on: September 5, 2025
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Antidepressant Drugs: MAOIs and Other Agents
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
